Innovating DNAse Enzymes

June 29, 2023 Patricia De La Madrid Comments: 0

Innovating DNAse Enzymes

In our latest project, we’re diving into the world of mRNA-based vaccines, aiming to optimize the production process for DNAse enzymes. This endeavor holds immense importance as it paves the way for the development of more robust and reproducible mRNA synthesis methods, ultimately enhancing the efficiency and scalability of vaccine production.

By focusing on industrializing and optimizing this critical aspect of mRNA synthesis, we’re contributing to the advancement of biopharmaceutical innovation and the potential for broader access to life-saving vaccines. Stay tuned as we embark on this groundbreaking journey towards a brighter future in healthcare.

RESEARCH AND DEVELOPMENT OF DNASE ENZYMES FOR THE SYNTHESIS OF ARNM-BASED VACCINES

Dossier no: FAR-010500-2023-3

Main objective of the project: development of a new robust, reproducible, industrialisable and optimised production process for DNAase enzymes involved in the synthesis of messenger RNA (mRNA).

Deadline for completion: From 29/06/2023 to 04/10/2025

Project funded by the European Union – Next Generation EU, the Ministry of Industry, Trade and Tourism and the Recovery, Transformation and Resilience Plan.

Grant awarded: 235,778.50€.

INVESTIGACIÓN Y DESARROLLO DE LAS ENZIMAS DNASAS PARA LA SÍNTESIS DE VACUNAS BASADAS EN ARNM

Nº expediente: FAR-010500-2023-3

Objetivo principal del proyecto: desarrollo de un nuevo proceso productivo robusto, reproducible, industrializable y optimizado de las enzimas DNAsas que participan en la síntesis del ARN mensajero (ARNm).

Plazo de realización: Desde el 29/06/2023 al 04/10/2025

Proyecto financiado por la Unión Europea – Next Generation EU, el Ministerio de Industria, Comercio y Turismo y el Plan de Recuperación Transformación y Resiliencia.

Subvención concedida: 235.778,50€

About 53Biologics:

53Biologics is a CDMO with specialized in biologics production, from pDNA to proteins. In order to serve as leaders in biologics development and manufacturing, our mission is to support you whenever you need us, starting in preclinical development up to commercialization.

For more information contact Patricia De La Madrid, Marketing & Business Development Manager at 53Biologics through this email: pdelamadrid@53biologics.com